Glenmark Pharmaceuticals Inc USA has announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), supplied in single-dose vials, further strengthening the company’s growing injectable medicines portfolio in the United States. The newly introduced product is approved as a bioequivalent and therapeutically equivalent alternative to the reference medicine Vimpat® Injection, marketed by UCB, Inc.
The launch reflects Glenmark’s continued focus on expanding access to high-quality and cost-effective treatment options for healthcare providers and patients across the country.Lacosamide is widely used in the management of neurological conditions requiring anti-seizure therapy and serves as an important treatment option within hospital and specialty care settings. The availability of an additional approved product is expected to contribute to supply stability while providing healthcare systems with greater choice. According to industry sales data, the U.S. market for the reference product generated annual sales of approximately $15 million during the twelve months ending April 2026, highlighting the ongoing demand for this therapeutic category.
Company executives noted that the launch forms part of a broader strategy aimed at building a diversified portfolio that includes complex formulations, injectables and specialty pharmaceutical products. By increasing its presence in the injectable segment, Glenmark is seeking to address evolving market needs while enhancing access to affordable medicines.
Over the past several years, the company has steadily expanded its footprint across the United States through a combination of product launches, manufacturing investments and portfolio development initiatives. The addition of Lacosamide Injection further strengthens its position within the competitive generic pharmaceutical market.
Glenmark’s global operations are supported by an extensive network of manufacturing facilities, research centers and commercial operations spanning multiple regions. The company continues to invest in product innovation while maintaining a strong emphasis on accessibility and affordability.
With operations in more than 80 countries, Glenmark has developed a diversified business across branded formulations, generics, specialty products and consumer healthcare. Its research and development efforts remain focused on addressing unmet medical needs in key therapeutic areas including respiratory care, dermatology and oncology.
Glenmark continues to strengthen its North American business through new product launches, portfolio expansion, and strategic investments in manufacturing and regulatory capabilities. The company believes its expanding injectable portfolio will support future growth opportunities in the US pharmaceutical market while reinforcing its commitment to delivering accessible and affordable healthcare solutions.
